<DOC>
	<DOC>NCT00813098</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.</brief_summary>
	<brief_title>Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Males and females aged 1870 years old Documented diagnosis of IBS (IBSdiarrhea or IBSmixed) based upon Rome III criteria Abdominal pain/discomfort at least 2 days per week during the screening and runin periods Normal structural evaluation of the colon within 5 years prior to screening Ability to provide written informed consent Inability to discontinue current drug therapy for IBS, except for bulking agents, through the duration of the study Use of anticholinergic antidepressants, opioid pain medications, or any drugs that affect bowel motility Lactose intolerance Major psychological disorder Significant nicotine or caffeine use (&gt;10 cigarettes and/or six 8 ounce cups of coffee per day, respectively)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>